Comparative serious safety reporting signals for antibody-drug conjugates versus HER2-targeted non-ADC therapies: A FAERS analysis (2020–2025).

Reshma L. Mahtani; Zouina Sarfraz; Naomi Dempsey; Lauren Carcas; Delia Constanza Guaqueta; Ana Cristina Sandoval-Leon

doi:10.1200/JCO.2026.44.16_suppl.e13084

Comparative serious safety reporting signals for antibody-drug conjugates versus HER2-targeted non-ADC therapies: A FAERS analysis (2020–2025).

Reshma L. Mahtani
, Zouina Sarfraz
, Naomi Dempsey
, Lauren Carcas
, Delia Constanza Guaqueta
, Ana Cristina Sandoval-Leon

Baptist Health South Florida

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	e13084-e13084
Journal	Journal of Clinical Oncology
Volume	44
Issue number	16
DOIs	https://doi.org/10.1200/JCO.2026.44.16_suppl.e13084
State	Published - Jun 2026

ASJC Scopus Subject Areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2026.44.16_suppl.e13084

Cite this

@article{1dafe88202554875b549975d8d2ed322,

title = "Comparative serious safety reporting signals for antibody-drug conjugates versus HER2-targeted non-ADC therapies: A FAERS analysis (2020–2025).",

author = "Mahtani, \{Reshma L.\} and Zouina Sarfraz and Naomi Dempsey and Lauren Carcas and Guaqueta, \{Delia Constanza\} and Sandoval-Leon, \{Ana Cristina\}",

note = "Publisher Copyright: {\textcopyright} 2026 by American Society of Clinical Oncology",

year = "2026",

month = jun,

doi = "10.1200/JCO.2026.44.16\_suppl.e13084",

language = "English",

volume = "44",

pages = "e13084--e13084",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

number = "16",

}

TY - JOUR

T1 - Comparative serious safety reporting signals for antibody-drug conjugates versus HER2-targeted non-ADC therapies

T2 - A FAERS analysis (2020–2025).

AU - Mahtani, Reshma L.

AU - Sarfraz, Zouina

AU - Dempsey, Naomi

AU - Carcas, Lauren

AU - Guaqueta, Delia Constanza

AU - Sandoval-Leon, Ana Cristina

PY - 2026/6

Y1 - 2026/6

UR - https://www.scopus.com/pages/publications/105041981621

UR - https://www.scopus.com/pages/publications/105041981621#tab=citedBy

U2 - 10.1200/JCO.2026.44.16_suppl.e13084

DO - 10.1200/JCO.2026.44.16_suppl.e13084

M3 - Article

AN - SCOPUS:105041981621

SN - 0732-183X

VL - 44

SP - e13084-e13084

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

ER -

Comparative serious safety reporting signals for antibody-drug conjugates versus HER2-targeted non-ADC therapies: A FAERS analysis (2020–2025).

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this